Clinical Trials Browser

Phase 2 × Axitinib × 90 days × Clear all

NCT07469683 2026-03-13

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

Carcinoma, Renal Cell, Neoplasms

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

Carcinoma, Renal Cell

NCT03297606 2026-03-04

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01409200 2026-03-03

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Phase 2 Completed

Lymphatic Metastasis

NCT07123090 2026-02-27

SPARCC

Phase 2 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05805501 2026-02-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT05327686 2026-01-14

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell